Isavuconazole + Repaglinide + Caffeine

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Pharmacokinetics of Repaglinide

Conditions

Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects

Trial Timeline

Jan 1, 2014 → Feb 1, 2014

About Isavuconazole + Repaglinide + Caffeine

Isavuconazole + Repaglinide + Caffeine is a phase 1 stage product being developed by Astellas Pharma for Pharmacokinetics of Repaglinide. The current trial status is completed. This product is registered under clinical trial identifier NCT02128321. Target conditions include Pharmacokinetics of Repaglinide, Pharmacokinetics of Caffeine, Healthy Subjects.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT02128321Phase 1Completed

Competing Products

20 competing products in Pharmacokinetics of Repaglinide

See all competitors